Healthtech Startups

Rematiq builds an AI-driven platform for product and regulatory compliance in life sciences, connecting requirements, regulations, evidence and submissions in one system and automating traceability, compliance checks and document generation. Each deployment includes an embedded domain team that handles integrations (e.g. Veeva, Polarion, SharePoint), validation and workflow rollout inside a customer's quality management system.

2 investors

Remedee Labs develops medical devices that use endorphin stimulation via wearable bracelets to treat rheumatologic pain conditions and fibromyalgia, primarily marketed in France.

2 investors

REMEDI8 provides compliance inspection, repair, and reporting services for fire safety systems in healthcare facilities, including fire doors, dampers, and barriers.

2 investors

Remedy Pharmaceuticals is a pharmaceutical company developing Cirara, an investigational drug studied in clinical trials for patients who have suffered a stroke. It focuses on treatments for serious neurological conditions.

2 investors

Remedy Plan is a biopharmaceutical company developing drugs that target NAMPT, an essential enzyme dysregulated in more than 20 diseases including cancer. Its lead clinical candidate, RPT1G, is a hyperbolic inhibitor designed to reduce NAMPT activity while avoiding the toxicity that has limited earlier attempts.

2 investors

Remmie Health develops AI-powered ear-nose-throat diagnostic solutions for families and telemedicine providers, using a digital otoscope and app to reduce unnecessary doctor visits and improve diagnostic accuracy in primary care.

2 investors

Renalyse is developing a point-of-care device for measuring creatinine and potassium in blood, intended as part of a platform for remote renal monitoring. It targets chronic kidney disease (CKD) management by connecting patients with healthcare professionals to provide real-time patient data to doctors.

2 investors

Renasant Bio is a biopharmaceutical company developing oral small molecule corrector and potentiator therapies to restore the function of polycystin 1 and 2 proteins in autosomal dominant polycystic kidney disease (ADPKD). Its pipeline targets the underlying biology of ADPKD across a range of mutations with the goal of halting and reversing disease progression.

2 investors

Reperio Health builds diagnostic tools and automated systems powered by AI/ML for enterprise deployment, with infrastructure for real-time data processing. The company serves large enterprises across technology and other sectors.

2 investors

Repertoire's Decode platform focuses on mapping the immune synapse — the interactions between T cell receptors, epitopes, and HLA molecules — to support the development of medicines targeting cancer and other diseases. It operates in immunology-based drug discovery and therapeutics.

2 investors

Resalis Therapeutics develops antisense oligonucleotide therapies targeting microRNA pathways for metabolic disorders. The company is advancing RES-010, a treatment candidate for obesity, fatty liver disease, and related metabolic disorders.

2 investors

Reset Pharma is a CNS-focused pharmaceutical company developing psilocybin and related psychedelics for the treatment of mental illness in patients with life-threatening diseases. It holds an exclusive worldwide license from NYU Langone Health for related intellectual property.

2 investors

Resilience Care develops digital remote patient monitoring solutions that capture and structure patient-reported data for oncology, psychiatry, and gastroenterology care. Its platform serves healthcare providers, patients, researchers, and life sciences companies to support clinical care and generate real-world evidence.

2 investors

ResistanceBio develops treatments to address drug resistance in cancer patients.

2 investors

Resistell develops a nanomotion-based diagnostic device for rapid phenotypic antibiotic susceptibility testing (AST), aimed at accelerating detection of antibiotic resistance in hospital settings. The Swiss company's IVD product is intended for clinical microbiology use with bacterial pathogens.

2 investors

Resolve Stroke develops software-driven ultrasound technology for medical imaging and diagnosis. The company serves healthcare providers and medical professionals in diagnostic and interventional radiology, with expertise in clinical development and device innovation.

2 investors

Resonant develops antibody-based therapeutics for oncology using deep cancer biology and drug discovery expertise. The company leverages world-class antibody engineering capabilities to advance oncology drug programs.

2 investors

Respiosa develops a minimally invasive surgical implant to treat obstructive sleep apnea by preventing tongue collapse during sleep, targeting patients for whom current treatments like CPAP are ineffective or poorly tolerated.

2 investors

Respira develops inhaled therapeutic products for pulmonary diseases, including a novel dry-powder inhalation device and lead product candidate RT234 for pulmonary arterial hypertension. The company focuses on creating drug-device combination products using advanced particle engineering and formulation technologies.

2 investors

Rest provides IoT-based smoke detection sensors and monitoring services for hotels to enforce no-smoking policies and maintain air quality. The system alerts hotel staff to smoking violations, reducing room recovery costs and improving guest experience.

2 investors

Restorative Neurotechnologies develops digital therapies certified as medical devices (MindLenses Professional) for cognitive rehabilitation in neurological conditions and neurodevelopmental disorders such as post-stroke recovery and ADHD, used in public and private healthcare facilities. It also offers MindPAth, a consumer-oriented cognitive training product, with a market focus in Italy and Europe.

2 investors

RestorixHealth develops and operates wound care centers in partnership with hospitals, delivers professional wound care services in nursing facilities and home settings, and coordinates wound care supplies to improve patient access and outcomes.

2 investors

2 investors

Rev Genomics uses genomic selection, tissue culture, and molecular analysis to develop high-value crop cultivars for breeders and seed banks. The company creates novel plant phenotypes and provides molecular fingerprinting and breeding technology primarily for specialty crops in California.

2 investors